PART B: VALORISATION PLAN
SECTION I: ESTIMATION OF COSTS
|
1 |
Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result. |
| … in terms of IPR protection | |
| A software can’t be protected by a patent.
Within European Union member states, indeed, a computer-implemented inventions which only solve a business problem using a computer, rather than a technical problem, are considered unpatentable as lacking an inventive step. Software is protected as works of literature under the Berne Convention. This allows the creator to prevent another entity from copying the program and there is generally no need to register code in order for it to be copyrighted. So, in this case the protection does not provide significant costs.
|
|
| …in terms of product development | |
|
In terms of product development, CRO needs a software developer for 1/3 of his/her time(15.000 €).
|
|
| …in terms of mass production | |
|
There are not specific mass production costs
|
|
| … in terms of marketing | |
|
There are not marketing costs |
|
|
2 |
Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs |
|||||
|
|
Year 1 |
Year 2 |
Year 3 |
Year 4 |
Year 5 |
|
|
Fixed costs |
|
|
|
|
|
|
|
Personnel |
35.000 |
35.000 |
35.000 |
|
|
|
|
Other running costs |
5.000 |
|
|
|
|
|
|
Marketing costs |
|
|
|
|
|
|
|
TOTAL EXPECTED COSTS |
40.000 |
35.000 |
35.000 |
|
|
|
|
Price per Unit |
1.000 |
1.000 |
1.000 |
|
|
|
|
Type of Unit |
|
|||||
|
Number of Units |
20 |
40 |
80 |
|
|
|
|
TOTAL Expected Revenues |
20.000 |
40.000 |
80.000 |
|
|
|
|
CASH FLOW REQUIRED (REVENUES-COSTS) |
(15.000) |
5.000 |
45.000 |
|
|
|
|
TOTAL CAPITAL required for five years |
15.000 |
|||||
SECTION 2: QUALITATIVE FACTORS
|
4 |
Dimension of identified target groups |
|
The target market of MnemoKairos database could be the hospital field. In Italy there are more than 1.500 private and public hospitals, so we can estimate more than 150.000 units all around the world. A potential market can be of about 500 users all over the world.
|
|
|
6 |
Evaluation of financial Risks for R&D result |
|
The project has no particular financial risks, because it doesn’t need any investment in fixed assets.
|
|
SECTION 3: IDENTIFICATION OF FINANCING SOURCES
After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)
Define relevance of the product with the following potential funding sources and comment |
|
|
|
1. …FP7 2. …FP8 3. … 4. … |
|
2 National Funding |
|
|
|
1. … LR 4/2005 (Friuli Venezia Giulia regional law for the development of innovative projects whose objective is the company growth) 2. …LR 26/2005 (Friuli Venezia Giulia regional law on innovation) 3. … 4. … … |
|
3 Private funding |
|
|
|
1. …Business Angel/Venture capitalist 2. … 3. … … |
|
4 Other |
|
|
|
|
SECTION 3: FINAL EVALUATION
| It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)… |
|
CRO has already developed the database and could verify the opportunity of selling it to other institutes and hospitals all over the world. Considering that this project doesn’t need further relevant resources, probably is not recommended the creation of a spin off. In any case it should be analyze the opportunity of partnerships and the funding opportunities in order to complete the database development.
|
Decision of evaluation (Please tick as appropriate)
|
|
The R&D has a high potential of exploitation |
|
þ |
The R&D result needs minor revisions |
|
|
The R&D result needs moderate revisions |
|
|
The R&D result needs major revisions |
|
|
The R&D result has no potential of exploitation |
Elisa Micelli
